Cosentyx (secukinumab) works by blocking a specific inflammatory protein called IL-17A. It’s a lab-made antibody that latches onto IL-17A before it can trigger the chain of inflammation responsible for conditions like plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. By intercepting this single protein, Cosentyx interrupts the inflammatory cycle at one of its key sources rather than suppressing the immune system broadly.
What IL-17A Does in Your Body
IL-17A is a signaling molecule your immune system uses to coordinate inflammation. In healthy people, it plays a role in fighting off infections, particularly fungal ones. But in autoimmune and inflammatory conditions, the body produces far too much of it, and that excess drives a destructive loop.
In psoriasis, IL-17A directly activates skin cells called keratinocytes, causing them to multiply too rapidly and pile up into the thick, scaly plaques characteristic of the disease. It also promotes the growth of new blood vessels in the skin (which contributes to redness), triggers the release of other inflammatory molecules like TNF-alpha and IL-6, and recruits more immune cells to the area. The result is a self-reinforcing cycle: inflammation begets more inflammation. In joints and the spine, the same protein drives the pain, swelling, and stiffness seen in psoriatic arthritis and ankylosing spondylitis.
How Cosentyx Stops the Cycle
Cosentyx is a fully human monoclonal antibody, meaning it was designed to look like a natural human immune protein so your body is less likely to reject it. Once injected, the antibody circulates through your bloodstream and binds directly to IL-17A molecules. This binding is highly specific: it physically prevents IL-17A from attaching to its receptor on the surface of cells like keratinocytes. Without that connection, the downstream cascade of inflammation never fires.
This targeted approach is what distinguishes Cosentyx from older, broader immunosuppressants. It doesn’t shut down your entire immune response. It removes one key driver of inflammation while leaving most of your immune defenses intact. That said, because IL-17A does play a legitimate role in fighting certain infections, blocking it comes with trade-offs (more on that below).
Conditions It Treats
Cosentyx is FDA-approved for six conditions, all connected by the role IL-17A plays in their underlying inflammation:
- Moderate to severe plaque psoriasis in patients 6 years and older
- Active psoriatic arthritis in patients 2 years and older
- Ankylosing spondylitis in adults
- Non-radiographic axial spondyloarthritis in adults with objective signs of inflammation
- Enthesitis-related arthritis in children 4 years and older
- Moderate to severe hidradenitis suppurativa in adults
The hidradenitis suppurativa approval is the most recent. In two large clinical trials (SUNSHINE and SUNRISE), 42% to 46% of patients receiving Cosentyx every two weeks saw at least a 50% reduction in abscesses and inflammatory nodules by week 16, compared with 31% to 34% on placebo.
How Well It Works for Psoriasis
The strongest efficacy data comes from plaque psoriasis. In a five-year study (SCULPTURE), about 89% of patients achieved at least a 75% improvement in their skin disease score by the end of year one. Two-thirds (68.5%) hit 90% improvement, and 44% achieved completely clear skin. These numbers held remarkably steady through five years: 88.5% still had 75% improvement, 66.4% maintained 90% improvement, and 41% still had fully clear skin.
That kind of long-term durability matters because psoriasis is a chronic condition, and many treatments lose effectiveness over time. For joint-related conditions like psoriatic arthritis, clinical trials showed rapid improvement in both joint and skin symptoms within the first 24 weeks, with benefits sustained through at least two years.
What the Treatment Schedule Looks Like
Cosentyx is given as a subcutaneous injection, meaning it goes just under the skin rather than into a vein. For most conditions, the standard dose is 300 mg. Treatment starts with a loading phase: injections at weeks 0, 1, 2, and 3. After that, you switch to one injection per month for ongoing maintenance. Each 300 mg dose is delivered as two separate 150 mg injections.
Most people self-inject at home after initial training, using a prefilled syringe or autoinjector pen. The loading phase front-loads the drug in your system to get results faster, while the monthly maintenance keeps IL-17A suppressed over the long term.
How Quickly You Can Expect Results
Many patients with psoriasis notice visible skin improvement within the first few weeks of treatment, during the loading phase. Clinical trials describe the onset as “rapid” for both skin and joint symptoms. For psoriatic arthritis, significant measurable improvement was documented by week 24, with continued gains beyond that point. The timeline varies by individual and by condition, but the loading phase is specifically designed to accelerate early response.
Common Side Effects
In a real-world study of 229 psoriasis patients, about 59% experienced at least one side effect. The most common was yeast (candidal) infection, reported in roughly 10% of patients. This makes biological sense: IL-17A is one of the body’s primary tools for fighting fungal infections, so blocking it creates an opening. These infections are typically mild and treatable, often appearing as oral thrush or yeast infections in skin folds.
Fatigue (about 7%) and nasopharyngitis, essentially a common cold (about 7%), were the next most frequently reported side effects. Most adverse events were mild to moderate and didn’t require stopping treatment.
The Link to Inflammatory Bowel Disease
One important consideration with Cosentyx is its relationship to inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis. IL-17A appears to have a protective role in the gut lining, so blocking it may weaken an already compromised intestinal barrier in susceptible people.
Across 21 clinical trials involving 7,355 patients, 41 cases of IBD were reported (0.56%). Of those, 30 were entirely new cases and 11 were flare-ups in people with a prior history. The rates did not increase with higher doses or longer treatment duration, which is somewhat reassuring. A small proof-of-concept trial actually tested Cosentyx as a treatment for Crohn’s disease and found it made the condition worse in some participants, confirming that IL-17A inhibition and active bowel inflammation are a poor match.
If you have a history of IBD or develop new gastrointestinal symptoms like persistent diarrhea, cramping, or bloody stools while on Cosentyx, that’s something to take seriously and bring to your doctor’s attention promptly.